Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474602 | 0.82 | MAPT (0.41) | P4HTMALDH1A1KDM4E | |
| SCHEMBL4481743 | 0.80 | TAS1R3 (0.46) | P4HTMLMNAGRM5RAB9AALDH1A1 | |
| SCHEMBL4480835 | 0.79 | HDAC1 (0.48) | P4HTM | |
| SCHEMBL4469287 | 0.76 | EGLN1 (0.43) | P4HTMRAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL8972504 | 0.76 | RAB9A (0.57) | LMNARAB9AALDH1A1ACACBNPC1 | |
| SCHEMBL4490213 | 0.75 | L3MBTL1 (0.52) | ALDH1A1 | |
| SCHEMBL4478208 | 0.71 | GABRA5 (0.40) | P4HTMGABRA5RAB9AALDH1A1NPC1 | |
| SCHEMBL4486555 | 0.70 | EGLN1 (0.43) | P4HTMRAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL16495421 | 0.69 | HPGDS (0.51) | LMNAGABRA5GRM5CTSA | |
| SCHEMBL13210632 | 0.67 | ALDH1A1 (0.55) | P4HTMLMNARAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | claimed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | claimed |
| US-7501451-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | FERTIG GEORG | 2006-04-27 | — | — | US | disclosed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC10, HDAC11 | P4HTM 692/4885LMNA 2940/4885GABRA5 2938/4885 |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | P4HTM 1825/4885LMNA 2946/4885GABRA5 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.